Breaking News, Collaborations & Alliances

Steritas Partners with argenx for Use of Its Steroid-Toxicity Clinical Outcome Assessments

Aims to advance evidence for novel steroid-sparing therapeutics.

Author Image

By: Charlie Sternberg

Associate Editor

Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, has entered a licensing agreement with argenx, a global immunology company, for use of its STOX Suite of steroid-toxicity clinical outcome assessments (COAs) across argenx’s development programs for differentiated immunology therapeutics.   The STOX Suite includes first-in-class digital instruments that provide a standardized and validated measure of the full scope of steroid-toxicity. The COAs can be applied in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters